Since our founding in 2017, we have had the privilege of participating in more than 385 R&D&I projects in the biomedical sector, supporting more than 220 clients in the creation and development of their spin-offs and start-ups. These achievements are the result of our shared commitment to our clients who have placed their trust in us and with whom we have had the pleasure of collaborating.

Below, you can read the opinions of some of these companies which develop everything from pharmaceuticals to medical devices:

Markus Wilhems

CEO and co-founder

What is the main activity of your company?
At MOWOOT we work to improve the quality of life of people with bowel dysfunctions such as chronic constipation. Our main product, “MOWOOT II – Bowel Management System”, is an innovative medical device that offers a non-pharmacological, safe and effective solution to stimulate intestinal transit.

What have you undertaken with GENESIS Biomed?
We have had the support of GENESIS Biomed in several key stages of MOWOOT’s growth. Their team has accompanied us in the preparation of private financing rounds, the raising of public funds and the strategic development of the company, among other fundamental aspects.

What has it been like working with us?
Our collaboration with GENESIS Biomed has been exceptional. We highlight their professionalism, transparency and ability to adapt to our needs, always adding value with their deep knowledge of the biomedical sector. Their agile and efficient approach makes them a key strategic partner for startups and growing companies.

David Segarra

CEO and co-founder

What is the main activity of your company?
AptaTargets develops therapeutic aptamers and, currently, our main activity is the development of ApTOLL, an aptamer for the treatment of stroke, among other indications.

What have you undertaken with GENESIS Biomed?
Our collaboration with GENESIS Biomed took place in the early stages of development, still in the preclinical stages, and was aimed at finalising the molecule’s development plan and the search for investors. At that time, as a small team, we needed the support of a consulting firm like GENESIS Biomed to advance in various aspects.

What has it been like working with us?
The collaboration was successful, thanks to the good work and involvement of Josep Lluís, the company was able to close its first round with specialised investors.

Pere del Campo

CEO and Co-founder

What is the main activity of your company?
CORNEA PROJECT develops innovative technologies for the molecular diagnosis of ocular pathologies, with a current focus on biomarkers for keratoconus and dry eye syndrome, facilitating more accurate diagnoses and helping to make treatments more personalised.

What have you undertaken with GENESIS Biomed?
We have worked together on various actions, including the definition of the financing strategy, the regulatory roadmap and the preparation of the business plan, among others, strengthening our preparation for future rounds of investment and commercial expansion.

What has it been like working with us?
The collaboration with GENESIS Biomed has been key to optimising our business strategy, providing an expert and personalised approach that has driven our growth and positioning in the biomedical and ophthalmology sector. It is always a pleasure to work and collaborate with GENESIS Biomed. The high quality and experience is evident in every delivery and every meeting.

These are some of the testimonials we have collected so far, but there are still many more that we will share on future occasions. GENESIS Biomed offers support to start-ups in the biomedicine sector in the development of their business activities, one of our main founding objectives.